@article{3995ee7f1b964e579548e3a0e0a063e6,
title = "A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer",
abstract = "Twenty-three evaluable patients with refractory epithelial ovarian cancer were treated with bisantrene (CL216,942). The drug was given as a single-dose injection every 3 weeks. One patient (4%) showed a partial response. The compound thus has limited activity against this malignancy.",
author = "Kavanagh, {John J.} and Gershenson, {David M.} and Saul, {Patton B.} and Copeland, {Larry J.}",
note = "Funding Information: {\textquoteright} Supported in part by Grant 4022 from American Cyanamid Company, Medical Research Division, Lederle Laboratories, Pearl River, N.Y. 01965. * To whom correspondence and reprint requests should be addressed: Department of Gynecology, P. 0. Box 67, M. D. Anderson Hospital, 6723 Bertner Avenue, Houston, Tex. 77030.",
year = "1986",
month = jan,
doi = "10.1016/0090-8258(86)90113-7",
language = "English (US)",
volume = "23",
pages = "40--43",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",
}